FDA halts California drugmaker's CAR-T trial after patient death

The FDA halted San Diego-based drugmaker Poseida Therapeutics' clinical trial of a CAR-T therapy after a patient died, according to an Aug. 17 Securities and Exchange Commission filing.

The phase 1 trial was investigating a CAR-T gene therapy called P-PSMA-101, designed to treat prostate cancer. 

The patient had metastatic castrate-resistant prostate cancer and died of liver failure 19 days after receiving the CAR-T treatment. He had missed two follow-up visits and developed symptoms that led to him  being hospitalized, according to the SEC filing. 

Poseida is waiting on a formal response from the FDA and preparing recommendations to allow the trial to resume, the drugmaker said. 

The drugmaker's shares fell 35 percent after the announcement.

More articles on pharmacy:
CVS partnering with Delta Air Lines for rapid COVID-19 testing program
Sanofi inks $3.68B deal to buy California autoimmune drugmaker
US to test benefits of remdesivir with second drug

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers